Voyager Therapeutics Overview
- Year Founded
-
2013

- Status
-
Public
- Employees
-
162

- Stock Symbol
-
VYGR

- Share Price
-
$4.23
- (As of Friday Closing)
Voyager Therapeutics General Information
Description
Voyager Therapeutics Inc is a gene therapy company focused on developing life-changing treatments for patients suffering from severe neurological diseases. It focuses on neurological diseases where an adeno-associated virus, or AAV, gene therapy approach that either increases or decreases the production of a specific protein can slow or reduce the symptoms experienced by patients, and therefore have a clinically meaningful impact. The company's gene therapy platform TRACER enables to engineer, optimize, manufacture and deliver AAV-based gene therapies that have the potential to provide durable efficacy following a single administration. Its pipeline of programs include, Anti-tau Antibody (VY-TAU01), SOD1 Silencing Gene Therapy (siRNA), FXN Gene Therapy among others.
Contact Information
Website
www.voyagertherapeutics.comCorporate Office
- 75 Hayden Avenue
- Lexington, MA 02421
- United States
Corporate Office
- 75 Hayden Avenue
- Lexington, MA 02421
- United States
Voyager Therapeutics Stock Performance
As of 14-Feb-2025, Voyager Therapeutics’s stock price is $4.23. Its current market cap is $231M with 54.6M shares.
(As of Friday Closing)
Stock Price | Previous Close | 52 wk Range | Market Cap | Shares | Average Volume | EPS |
---|---|---|---|---|---|---|
$4.23 | $4.38 | $4.00 - $10.66 | $231M | 54.6M | 429K | $0.70 |
Voyager Therapeutics Financials Summary
As of 30-Sep-2024, Voyager Therapeutics has a trailing 12-month revenue of $164M.
In Thousands, USD |
TTM 30-Sep-2024 | FY 2023 31-Dec-2023 | FY 2022 31-Dec-2022 | FY 2021 31-Dec-2021 |
---|---|---|---|---|
EV | (5,060) | 139,410 | 127,637 | 26,625 |
Revenue | 163,784 | 250,008 | 40,907 | 37,415 |
EBITDA | 14,350 | 126,458 | (41,993) | (65,642) |
Net Income | 25,880 | 132,330 | (46,408) | (71,197) |
Total Assets | 426,041 | 351,281 | 159,356 | 193,855 |
Total Debt | 45,347 | 20,293 | 23,126 | 44,179 |
Voyager Therapeutics Valuation & Funding
Deal Type | Date | Amount | Valuation/ EBITDA |
Post-Val | Status | Debt |
---|
Voyager Therapeutics Comparisons
Industry
Financing
Details
Voyager Therapeutics Competitors (58)
One of Voyager Therapeutics’s 58 competitors is Regenxbio, a Formerly VC-backed company based in Rockville, MD.
Company Name | Financing Status | Location | Employees | Total Raised | Last Financing Date/Type | Last Financing Amount |
---|---|---|---|---|---|---|
Regenxbio | Formerly VC-backed | Rockville, MD | ||||
Intellia Therapeutics | Formerly VC-backed | Cambridge, MA | ||||
Anokion | Venture Capital-Backed | Ecublens, Switzerland | ||||
Forge Biologics | Formerly VC-backed | Grove City, OH | ||||
NexImmune | Formerly VC-backed | Gaithersburg, MD |
Voyager Therapeutics Patents
Voyager Therapeutics Recent Patent Activity
Publication ID | Patent Title | Status | First Filing Date | Technology (CPC) | Citations |
---|---|---|---|---|---|
US-20240391988-A1 | Tau binding compounds | Pending | 15-Sep-2022 | ||
AU-2023320453-A1 | Compositions and methods for crossing the blood brain barrier | Pending | 03-Aug-2022 | ||
AU-2023279090-A1 | Aav capsid variants and uses thereof | Pending | 02-Jun-2022 | ||
AU-2023217698-A1 | Aav capsid variants and uses thereof | Pending | 08-Feb-2022 | ||
EP-4476241-A1 | Aav capsid variants and uses thereof | Pending | 08-Feb-2022 | C07K14/005 |
Voyager Therapeutics Signals
Voyager Therapeutics ESG
Risk Overview
Risk Rating
Updated January, 20, 2020
41.94 | Severe Risk
Risk Scale
A lower score indicates better sustainability
Negl
0-10
Low
10-20
Med
20-30
High
30-40
Severe
40+
Exposure
Exposure refers to the extent to which a company is exposed to different material ESG issues
Management
Management is related to actions taken to manage ESG issues
Peers Analysis
Peer performance insights compare the company’s ESG performance to the performance of selected peers to help inform future ESG decisions and drive internal performance improvements.
Global
Covered Companies
of 14,042
Rank
Percentile

Pharmaceuticals
Industry
of 947
Rank
Percentile

Biotechnology
Subindustry
of 427
Rank
Percentile

Voyager Therapeutics FAQs
-
When was Voyager Therapeutics founded?
Voyager Therapeutics was founded in 2013.
-
Where is Voyager Therapeutics headquartered?
Voyager Therapeutics is headquartered in Lexington, MA.
-
What is the size of Voyager Therapeutics?
Voyager Therapeutics has 162 total employees.
-
What industry is Voyager Therapeutics in?
Voyager Therapeutics’s primary industry is Biotechnology.
-
Is Voyager Therapeutics a private or public company?
Voyager Therapeutics is a Public company.
-
What is Voyager Therapeutics’s stock symbol?
The ticker symbol for Voyager Therapeutics is VYGR.
-
What is the current stock price of Voyager Therapeutics?
As of 14-Feb-2025 the stock price of Voyager Therapeutics is $4.23.
-
What is the current market cap of Voyager Therapeutics?
The current market capitalization of Voyager Therapeutics is $231M.
-
What is Voyager Therapeutics’s current revenue?
The trailing twelve month revenue for Voyager Therapeutics is $164M.
-
Who are Voyager Therapeutics’s competitors?
Regenxbio, Intellia Therapeutics, Anokion, Forge Biologics, and NexImmune are some of the 58 competitors of Voyager Therapeutics.
-
What is Voyager Therapeutics’s annual earnings per share (EPS)?
Voyager Therapeutics’s EPS for 12 months was $0.70.
Data Transparency
-
Meet our data hygiene team
Discover how our experts ensure you’re getting the most accurate financial data in the industry.
Read blog » -
How PitchBook sources data
Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.
Discover our process »